Shandong Sinobioway Biomedicine Co Ltd Market Cap ($404.50 Million)
Market Cap & Net Worth: Shandong Sinobioway Biomedicine Co Ltd (002581)
Shandong Sinobioway Biomedicine Co Ltd market cap. Shandong Sinobioway Biomedicine Co Ltd (SHE:002581) has a market capitalization of $404.50 Million (CN¥2.76 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #13032 globally and #3813 in its home market, demonstrating a -9.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Sinobioway Biomedicine Co Ltd's stock price CN¥4.19 by its total outstanding shares 659735586 (659.74 Million). Also see 002581 cash generation efficiency for how efficiently the company converts equity into cash flow.
Shandong Sinobioway Biomedicine Co Ltd Market Cap History (2015–2026)
Shandong Sinobioway Biomedicine Co Ltd market cap history from 2015 to 2026. Data shows change from $3.35 Billion to $404.50 Million (-16.03% CAGR). Check Shandong Sinobioway Biomedicine Co Ltd share price for real-time trading data and today's change.
Shandong Sinobioway Biomedicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 002581 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.63x
Shandong Sinobioway Biomedicine Co Ltd's market cap is 2.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.34 Billion | $1.26 Billion | $417.70 Million | 1.85x | 5.61x |
| 2017 | $1.85 Billion | $1.16 Billion | $388.41 Million | 1.59x | 4.76x |
| 2018 | $623.65 Million | $664.59 Million | -$103.75 Million | 0.94x | N/A |
| 2019 | $698.95 Million | $567.64 Million | $63.38 Million | 1.23x | 11.03x |
| 2020 | $1.77 Billion | $276.83 Million | -$195.93 Million | 6.39x | N/A |
| 2021 | $2.06 Billion | $402.71 Million | $271.00 Million | 5.12x | 7.61x |
| 2022 | $1.52 Billion | $357.08 Million | -$14.68 Million | 4.26x | N/A |
| 2023 | $1.41 Billion | $429.79 Million | -$332.46 Million | 3.28x | N/A |
| 2024 | $1.03 Billion | $360.41 Million | -$137.31 Million | 2.85x | N/A |
| 2025 | $724.05 Million | $274.81 Million | -$116.28 Million | 2.63x | N/A |
Competitor Companies of 002581 by Market Capitalization
Companies near Shandong Sinobioway Biomedicine Co Ltd in the global market cap rankings as of November 5, 2026. Also see Shandong Sinobioway Biomedicine Co Ltd assets under control for a full breakdown of the balance sheet.
Key companies related to Shandong Sinobioway Biomedicine Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Shandong Sinobioway Biomedicine Co Ltd (2015–2026)
Market capitalization of Shandong Sinobioway Biomedicine Co Ltd from 2015 to today. Between 2015 and today, Shandong Sinobioway Biomedicine Co Ltd's market cap moved from $3.35 Billion to $ 404.50 Million, with a yearly change of -16.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥404.50 Million | -44.13% |
| 2025 | CN¥724.05 Million | -29.51% |
| 2024 | CN¥1.03 Billion | -27.12% |
| 2023 | CN¥1.41 Billion | -7.30% |
| 2022 | CN¥1.52 Billion | -26.23% |
| 2021 | CN¥2.06 Billion | +16.48% |
| 2020 | CN¥1.77 Billion | +153.18% |
| 2019 | CN¥698.95 Million | +12.07% |
| 2018 | CN¥623.65 Million | -66.30% |
| 2017 | CN¥1.85 Billion | -21.01% |
| 2016 | CN¥2.34 Billion | -30.07% |
| 2015 | CN¥3.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Shandong Sinobioway Biomedicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $404.50 Million USD |
| MoneyControl | $404.50 Million USD |
| MarketWatch | $404.50 Million USD |
| marketcap.company | $404.50 Million USD |
| Reuters | $404.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. It offers injectable mouse nerve growth factor, human interferon, vaccines, traditional Chinese medicine decoction pieces, and pharmaceutical distribution. The company was founded in 1998 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Y… Read more